The Life Sciences team advised Third Arc Bio in its launch with oversubscribed $165 million Series A financing. The funding will advance the company through clinical studies to address significant unmet needs in oncology and autoimmunity. The Series A investor syndicate was led by Vida Ventures and co-led by Cormorant Asset Management and Hillhouse Investment, with continued support from Omega Funds.
Third Arc Bio is a biotech company developing multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. The company's drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging two technologies that power a pipeline of high value therapeutics – a solid tumor synergy platform and an I&I platform that offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. Third Arc Bio's leadership team has collectively brought 19 drugs from discovery and development to commercialization.
The Goodwin team was led by Danielle Lauzon, Dan Hughes, Larissa Pinho, and Libby Sousa.
For additional details on the agreement, please read the press release.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.